The global sinusitis treatment market was
valued at USD 3.0 billion in 2021 and is projected to expand
at a CAGR of 5.2% during
the forecast period of 2022-2030.
As per the reports
of Sinus & Allergy Wellness Center 2021, more than 30.0 million people are
affected by sinusitis in the U.S. each year. Sinusitis is observed in children
as well as adults and is one of the most common infections of the upper
respiratory tract system worldwide.
Sinusitis is an
inflammation of the mucosal lining of the paranasal sinuses located in the
skull. It is caused by virus, fungi, bacteria and microbes. Viral sinusitis is
the common form of sinusitis and does not require antibiotics. Bacterial
sinusitis, however, is lesser prevalent than viral sinusitis and requires doses
Sinusitis can be
acute, sub-acute, or chronic. Usually, the condition causes extreme discomfort,
and in uncontrolled advanced stages, it can also lead to complications such as
brain abscess and meningitis if it is not treated or detected. The first-line
treatment of sinusitis is antibiotics followed by decongestants and surgery at
Factors such as the proliferating base of common cold and sinusitis
patients across the globe, the growing demand for enhanced diagnostic practices
as well as development of advanced antibiotics, the surging upper respiratory
tract infections cases across the world and the increasing pollution levels especially
across the developing regions are the primary factors driving the growth of the
global sinusitis treatment market.
Additionally, companies and hospitals' growing initiatives and education
programs focused on creating awareness among patients regarding the need for a
potent therapeutic approach for sinusitis management and treatment have been
successful increasing the adoption rate of treatments globally. In turn, the
drug manufacturers are forced to develop and commercialize new therapeutic
measures and bring advanced and innovative respiratory treatments and
diagnostic procedures in the healthcare system. This has led to the advent of
advanced devices such as an enhanced intra-nasal drug delivery which aids in the
improvement of patient’s quality of life and the new nasal spray which delivers
drugs in hard-to-reach cavities of patient’s sinuses. Others devices that enable patients to treat
themselves at home to minimize symptoms of chronic sinusitis in its early
stages are also underway. The increasing number of technological innovations by
manufacturers is thus; set to bring incremental growth opportunities for the
global sinusitis treatment market in the upcoming years.
Moreover, the investments made by drug manufacturers on R&D activities
for receiving regulatory approvals by government authorities have been rising
tremendously since the last few years. As a result, the number of approvals is
also growing. This rising investment and approval rate of drugs and treatments
are expected to further bolster the growth of the market during the forecast
Furthermore, other factors such as innovation in diagnostic tests and
antibodies production, the surging number of factors inclining people to
sinusitis, the increasing use of various medications for treatment such as
nasal sprays, nasal corticosteroids, and decongestants and the burgeoning demand
for better treatment options for acute and chronic sinusitis and other
associated disorders such as asthma in same patients are expected to further
augment the growth of the global sinusitis treatment market during the forecast
such as the high cost of diagnostic
tests, the side effects associated with corticosteroids, and the growing
concerns regarding affordability and availability of the tests are anticipated
to restrain the growth of the global sinusitis treatment market up to some
extent during the forecast period.
SINUSITIS TREATMENT MARKET SEGMENTATION
o Penicillin/ Β-lactamase inhibitor combinations
Decongestant and mucolytic
o A1 receptor agonist
o Imidazoline derivatives
By Route of
By Distribution Channel
Middle East and Africa
Based on disease, the acute sinusitis segment accounted for the largest market
share of 36.0% in the global sinusitis treatment market in 2021 and is
projected to further retain its dominance in the market by expanding at a CAGR
of 4.1% during the forecast period. The segment's growth can be attributed to
the increasing incidences of common cold & flu cases among people leading
to enhanced cases of acute sinusitis globally.
Based on route of administration, the oral segment held the largest market
share of 61.0% in the global sinusitis treatment market in 2021. The segment is
anticipated to further maintain this trend over the forecast period as it is the
most commonly used route of administration due to its several advantages,
including feasibility, ease of administration, intensified immune response, and
Based on distribution channel, the retail pharmacies segment led the
global sinusitis treatment market in 2021 by acquiring a market share of 45.0%.
It is estimated that the segment will continue to lead the market further
during the forecast period of 2022-2030. However, the hospital pharmacies
segment is expected to witness growth at the highest CAGR in the market during
the forecast period owing to the availability of funds and growing demand from
Based on treatment, the antihistamines sub-segment held over 32.0% market
share and dominated in the global sinusitis treatment market in 2021. The
segment is predicted to further register growth at a CAGR of 3.85% from 2023 to 2030.
The growth of the segment can be attributed to the growing usage of these drugs
to relieve allergy, cold and sinus symptoms. The antibiotics segment held the
second largest share in the global market in 2021 and is expected to witness
substantial growth in the market during the forecast period. This is because due
to the surging consciousness among people regarding antibiotics, their easily
availability and the escalating number of companies investing in the
development of antibiotics. However, the decongestant & mucolytic and
NSAIDS segments are expected to witness the fastest growth in the market during
the forecast period.
The North American
region accounted for the largest share in the global sinusitis treatment market
in 2021 followed by Europe. The region is expected to further maintain its
position at the top during the forecast period. The growth of the market in the
region can be attributed to which the growing incidence sinusitis and chronic
diseases cases in the region, the high presence of well-established players,
the rising awareness level, the increasing adoption of new technologies and the
growing developments in sinus surgery in the region. The major contributor to
the growth of the region is the United States.
region held the second largest share in the global sinusitis treatment market
in 2021 and is expected to grow at a robust growth rate over the forecast
period further. The growth in the region
can be attributed to the burgeoning number of invasive bacterial diseases and the
increasing number strategic partnership between academic research institutes
and major pharmaceutical players for the formulation and development of
medicines employed for the treatment of sinusitis infection in the region.
The Asia Pacific
region is predicted to be the fastest-growing regional sinusitis treatment
market during the forecast period. The growth in the region can be attributed
to the increasing cases of acute bacterial sinusitis infection, the soaring
pollution levels and the advancing healthcare infrastructure in the region.
Furthermore, the rapidly proliferating population, the surging disposable
incomes and healthcare spending of people, the high prevalence of unhealthy lifestyles,
and the growing number of R&D activities in the region are also expected to
significantly contribute to the growth of the global sinusitis treatment market
during the forecast period. The major contributors to the region include India,
China and Japan.
KEY COMPANIES IN SINUSITIS TREATMENT MARKET
Teva Pharmaceutical Industries Ltd.
Abbott Laboratories Inc.
Eli Lilly and Company
Sun Pharmaceutical Industries Inc.
Janssen Pharmaceuticals Inc.
Dr. Reddy's Laboratories Inc.
Merck & Co. Inc.
Hikma Pharmaceuticals plc